Collegium Pharmaceutical, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Collegium Pharmaceutical, Inc. (COLL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $17.10 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-02-26
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $17.10.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $17.10, a 35.71% increase from fiscal 2021.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $12.60, a 1.41% decline from fiscal 2020.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $12.78, a 40.90% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|
| 2024-12-31 | $17.10 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $17.10 10-K · filed 2025-02-27 | $0.00 10-K · filed 2023-02-23 | ||
| 2021-12-31 | $12.60 10-K · filed 2024-02-22 | |||
| 2020-12-31 | $12.78 10-K · filed 2023-02-23 | |||
| 2020-09-30 | $12.78 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $12.83 10-Q · filed 2020-08-05 | |||
| 2019-12-31 | $9.07 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $8.98 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $9.36 10-Q · filed 2020-08-05 | |||
| 2018-12-31 | $14.51 10-K · filed 2021-02-25 | |||
| 2017-12-31 | $7.86 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |